funding is the sole category represented across all 1 tracked stories. Sift Biosciences is most often covered alongside Lifespan Vision Ventures, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 3 original sources each against 2.4 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Sift Biosciences
funding is the sole category represented across all 1 tracked stories. Sift Biosciences is most often covered alongside Lifespan Vision Ventures, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 3 original sources each against 2.4 for the same window. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. We currently track 1 Biotech story that mention Sift Biosciences, all published on February 19, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Sift Biosciences. Shared-story counts are live from our verified record — not editorial picks.
Sift Biosciences has secured $3.7 million in a pre-seed financing round co-led by Lifespan Vision Ventures to advance its innovative technology platform. The investment underscores a growing trend of early-stage capital flowing into biotech startups focused on longevity and age-related diseases.